coenzyme-q10 and Anxiety-Disorders

Most suicidality literature in Huntington disease (HD) is based on natural history studies or retrospective reviews, but reports on risk factors from clinical trials are limited.. We analyzed 609 participants from 2CARE, a randomized, double-blind, placebo-controlled clinical trial with up to 5 years of follow-up, for risk factors related to suicidality. The primary outcome variable was the time from randomization until the first occurrence of either suicidal ideation or attempt. We also considered time from randomization until the first suicide attempt as a secondary outcome variable.. These data suggest psychiatric comorbidities in HD are predictive of suicidal behavior while participating in clinical trials, reinforcing the importance of clinical surveillance and treatment towards lessening risk during participation and perhaps beyond. Designing a composite algorithm for early prediction of suicide attempts in HD may be of value, particularly given anticipated trials aimed at disease modification are likely to be long-term.. NCT00608881.

Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Depressive Disorder; Employment; Female; Humans; Huntingtin Protein; Huntington Disease; Male; Marital Status; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Suicidal Ideation; Suicide, Attempted; Tetrabenazine; Trinucleotide Repeat Expansion; Ubiquinone; Vitamins